Jean Bergeron is a physician acting as consultant and clinical scientist at the, Endocrinology and Nephrology Research Unit, Centre de recherche du CHU de Québec – Université Laval, as well as Professor at the Molecular Biology, Medical Biochimistry and Pathology Department, Faculty of Medicine, Laval University. He is member of the Medical Biochimistry Unit (Department of Laboratory Medicine) and chief of the Lipid clinic (Department of Medicine) of the CHU de Québec-Université Laval. He is also Secretary for the Société Québécoise de Lipidologie, Nutrition et Métabolisme (SQLNM), a scientific society from which he received in 2012 a recognition award, Le prix des Fondateurs Jean Davignon et Paul-J. Lupien, for his outstanding contribution in the field of lipidology. As specialist in laboratory medicine and lipidology, he supervises the CHU de Québec – Laval University clinical lipid laboratory performing lipoprotein, lipid and gene analyses.
Interest in clinical research
During his career, he has been dedicated to a better understanding of clinical and biological expressions of primary and secondary hyperlipidemia. He has also participated in the development and application of up to date lipid guidelines for clinicians and contributed to the characterization of new metabolic markers related to atherosclerosis and heart disease. He participated to numerous clinical trials using statins and new emergent therapies in lipoprotein metabolism.
Actual clinical research
More recently, he is involved in research on statin-generated myopathy, including identification of blood or genetic markers related to statin side effect and development of clinical tools for a better support to patients suffering from this condition. He is involved in the Canadian Familial Hypercholesterolemia registry. Finally, he is principal investigator in several clinical trials using PCSK9 inhibitors, anti-sense oligonucleotides, ANGPTL-3 inhibitors, and in some cases, gene therapy for very severe hypercholesterolemia or patients at very high CV risk for premature atherosclerotic heart disease.
2705, boulevard Laurier
C-00-224
Québec, Québec
Canada G1V 4G2
Latest news
Data not available
- Chitdamrong, BounmyEmployeeCHUL+1 418-525-4444, extension 47125+1 418-654-2145bounmy.chitdamrong@chudequebec.cabounmy.chitdamrong@crchudequebec.ulaval.ca
2705, boulevard Laurier
C-00102
Québec, Québec
Canada G1V 4G2 - Laflamme, NathalieEmployeeCHUL+1 418-525-4444, extension 47117+1 418-654-2277nathalie.laflamme.2@crchudequebec.ulaval.ca
2705, boulevard Laurier
C-00102
Québec, Québec
Canada G1V 4G2
Impact of statin withdrawal on perceived and objective muscle function
Journal ArticlePLoS One, 18 (6), 2023.
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial
Journal ArticleNat Med, 29 (3), 2023.
A case of eruptive xanthomas associated with pregnancy unmasking a G188E heterozygous mutation of the lipoprotein lipase gene: A case report
Journal ArticleSAGE Open Med Case Rep, 10 , 2022.
Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia
Journal ArticleJ Clin Lipidol, 16 (5), 2022.
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT
Journal ArticleLancet Diabetes Endocrinol, 10 (10), 2022.
Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study
Journal ArticleCJC Open, 4 (6), 2022.
Intra-abdominal adipose depot variation in adipogenesis, lipogenesis, angiogenesis, and fibrosis gene expression and relationships with insulin resistance and inflammation in premenopausal women with severe obesity
Journal ArticleJ Physiol Biochem, 78 (2), 2022.
Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry
Journal ArticleCan J Cardiol, 38 (3), 2022.
Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial
Journal ArticleJ Clin Lipidol, 14 (1), 2020.
Adiposity, lifestyle and vitamin D levels: the quest for answers
Journal ArticleInt J Obes (Lond), 44 (7), 2020.
Recently finished projects
- Support clinico-administratif pour patients et médecins pour l'utilisation de nouveaux agents biologiques pour le traitement de l'hypercholestérolémie, from 2019-01-30 to 2023-03-31